Regenxbio Return on Equity (ROE) Growth & History (RGNX)
Regenxbio's return on equity was −107.00% for fiscal 2025.
View full Regenxbio company overviewRegenxbio annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −107.00% | −27.51 pp |
| 2024 | 2024-12-31 | −79.49% | −15.84 pp |
| 2023 | 2023-12-31 | −63.65% | −19.87 pp |
| 2022 | 2022-12-31 | −43.78% | −66.17 pp |
| 2021 | 2021-12-31 | 22.39% | +49.26 pp |
| 2020 | 2020-12-31 | −26.87% | −7.12 pp |
| 2019 | 2019-12-31 | −19.76% | −48.64 pp |
| 2018 | 2018-12-31 | 28.89% | +71.33 pp |
| 2017 | 2017-12-31 | −42.45% | −9.18 pp |
| 2016 | 2016-12-31 | −33.27% | −10.29 pp |
| 2015 | 2015-12-31 | −22.98% | — |
Regenxbio quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 48.92% | +77.97 pp |
| Q1 2026 | 2026-03-31 | −145.46% | −147.74 pp |
| Q4 2025 | 2025-12-31 | −50.83% | −32.59 pp |
| Q3 2025 | 2025-09-30 | −33.02% | −14.68 pp |
| Q2 2025 | 2025-06-30 | −29.05% | −14.71 pp |
| Q1 2025 | 2025-03-31 | 2.28% | +20.31 pp |
| Q4 2024 | 2024-12-31 | −18.25% | +0.39 pp |
| Q3 2024 | 2024-09-30 | −18.35% | −2.26 pp |
| Q2 2024 | 2024-06-30 | −14.34% | +2.20 pp |
| Q1 2024 | 2024-03-31 | −18.03% | −4.44 pp |
| Q4 2023 | 2023-12-31 | −18.64% | −7.54 pp |
| Q3 2023 | 2023-09-30 | −16.09% | −3.45 pp |
| Q2 2023 | 2023-06-30 | −16.55% | −6.22 pp |
| Q1 2023 | 2023-03-31 | −13.59% | −3.04 pp |
| Q4 2022 | 2022-12-31 | −11.10% | −59.07 pp |
| Q3 2022 | 2022-09-30 | −12.64% | −0.58 pp |
| Q2 2022 | 2022-06-30 | −10.33% | +0.53 pp |
| Q1 2022 | 2022-03-31 | −10.55% | +0.20 pp |
| Q4 2021 | 2021-12-31 | 47.98% | +59.63 pp |
| Q3 2021 | 2021-09-30 | −12.06% | −14.22 pp |
| Q2 2021 | 2021-06-30 | −10.86% | −2.60 pp |
| Q1 2021 | 2021-03-31 | −10.76% | −1.56 pp |
| Q4 2020 | 2020-12-31 | −11.66% | −5.89 pp |
| Q3 2020 | 2020-09-30 | 2.16% | +9.34 pp |
| Q2 2020 | 2020-06-30 | −8.25% | −7.96 pp |
| Q1 2020 | 2020-03-31 | −9.20% | −2.73 pp |
| Q4 2019 | 2019-12-31 | −5.76% | −6.62 pp |
| Q3 2019 | 2019-09-30 | −7.18% | −2.45 pp |
| Q2 2019 | 2019-06-30 | −0.30% | −3.73 pp |
| Q1 2019 | 2019-03-31 | −6.47% | −49.69 pp |
| Q4 2018 | 2018-12-31 | 0.86% | +9.33 pp |
| Q3 2018 | 2018-09-30 | −4.73% | +5.46 pp |
| Q2 2018 | 2018-06-30 | 3.44% | +10.25 pp |
| Q1 2018 | 2018-03-31 | 43.22% | +54.96 pp |
| Q4 2017 | 2017-12-31 | −8.47% | +3.00 pp |
| Q3 2017 | 2017-09-30 | −10.19% | −0.55 pp |
| Q2 2017 | 2017-06-30 | −6.82% | +0.32 pp |
| Q1 2017 | 2017-03-31 | −11.74% | −6.68 pp |
| Q4 2016 | 2016-12-31 | −11.47% | −9.11 pp |
| Q3 2016 | 2016-09-30 | −9.65% | −2.44 pp |
| Q2 2016 | 2016-06-30 | −7.13% | — |
| Q1 2016 | 2016-03-31 | −5.06% | — |
| Q4 2015 | 2015-12-31 | −2.36% | — |
| Q3 2015 | 2015-09-30 | −7.21% | — |
Regenxbio return on equity trends
Over the last five fiscal years, Regenxbio's return on equity decreased from −26.87% to −107.00%, a change of −80.13 percentage points. The latest reported quarter, Q2 2026, shows 48.92%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regenxbio source filings ↗